Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)

NCT02014636 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Pazopanib
DRUG: MK-3475

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]